**3. Molecular targeted therapy**

Several small-molecule, orally available RTK inhibitors exhibit an antiangiogenic effect of inhibiting VEGF and other kinases. They are expected to have high clinical utility and are currently being tested in clinical trials of varying stages for the treatment of advanced HCC (**Table 1**).


**Table 1.** Molecularly targeted antiangiogenic agents for advanced HCC.

## **3.1. Sorafenib**

of tissue growth and regeneration. Abnormal pathological angiogenesis is observed in patients with rheumatoid arthritis, psoriasis, diabetic retinopathy, fibrogenesis, and tumor growth [1]. Although early studies were conducted to determine the molecular processes associated with carcinogenesis and angiogenesis that were performed independently, more recent studies have

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading cause of cancer-related mortality worldwide, accounting for more than 600,000 new cases annually. The greatest risk factors for developing HCC include liver cirrhosis induced by hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, excessive alcohol intake, and metabolic syndrome. Regardless of the etiology, since HCC commonly develops in patients with a chronic liver disease (e.g., liver cirrhosis) only approximately one-third of the patients diagnosed with HCC are eligible for curative treatments (e.g., surgical resection) [3]. Consequently, several alternative therapies have been employed, including percutaneous radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). However, no satisfactory improvement of HCC prognosis has been achieved to date. The notable characteristic of HCC that accounts for its poor prognosis is the risk of high frequency in recurrence attributed to intrahepatic metastasis or the multicentric development. The key feature of HCC progression is also hypervascularity formed by intratumoral angiogenesis as well as the frequent recurrence. Several studies have demonstrated that angiogenesis is implicated in the survival and growth of HCC. It has also been reported that angiogenesis can be induced during the early stages of tumor formation and the various carcinogenic mechanisms have been demonstrated in several different experimental models [4–7]. Therefore, several antiangiogenic agents (i.e.,

In this chapter, mechanistic insights into angiogenesis and its contribution to hepatocarcinogenesis will initially be reviewed. In addition, newly developed antiangiogenic agents will be

In HCC, tumor angiogenesis leads to a pathologic vascularization pattern, of which intratumoral vascularization is critical for the diagnosis and treatment of HCC, as well as for pathogenesis and patient prognosis [1, 8, 9]. In general, HCC is supplied with blood flow primarily via the hepatic arteries, while noncancerous lesions and the normal liver parenchyma are supplied predominantly by the portal vein. This distinct vascularization is clinically utilized to diagnose HCC radiographically by emphasizing the tumor lesions. Any tumor mass

Of the various proangiogenic factors, vascular endothelial growth factor (VEGF) is one of the most potent and required for both physiological and pathological angiogenesis [11]. VEGF induces EC proliferation, promotes migration and differentiation as well as stimulates permeabilization of blood vessels and vasculogenesis. The several forms of VEGF bind to

depends entirely on the formation of a vascular network that provides the

revealed that both biological phenomena emerge synergistically [2].

412 Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy

sorafenib) have been developed as novel treatment options for HCC.

growing tumor with oxygen and essential nutrients [10].

described in detail.

more than 1–2 mm3

**2. Angiogenesis in HCC**

Sorafenib (Nexavar®) was developed in 1995 and is the only chemotherapeutic drug that has demonstrated to improve the survival rate in patients with HCC [18, 19]. Sorafenib acts by inhibiting the RAF serine/threonine kinases that play a key role in the transduction of mitogenic and oncogenic pathways through the Raf/mitogen-activated protein kinase (MEK)/ extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) signaling pathway [20]. Such signaling results in a lower cyclin D1 expression as well as cell cycle arrest. Sorafenib also potently inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3, and c-Kit, which promote angiogenesis [19, 20]. The repression blocks a broad spectrum of different processes involved in proliferation, angiogenesis, or apoptosis, causing a reduction in the blood vessel regions of the tumor and the starving of cancerous cells. Furthermore, sorafenib enhances tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death through an SH2 domain, which causes a tyrosine phosphatase (SHP-1)-dependent reduction of signal transducers and activators of transcription type 3 (STAT3) phosphorylation and the related protein myeloid cell leukemia 1 (Mcl-1) (i.e., survivin and cyclin D1) in HCC cells [21]. Sorafenib is also able to repress Mcl-1 activity through an MAPK-independent mechanism, which increases the intrinsic apoptosis pathway in tumor cells. Moreover, recent studies have claimed that the eukaryotic translation initiation factor 4E (eIF4E) might be implicated in sorafenib-dependent Mcl-1 inhibition [22]. Clinically, sorafenib can extend the mean patient survival from 7.9 to 10.7 months [19]. Representative adverse events caused by the treatment of sorafenib consist of diarrhea, weight loss, hand-foot skin reaction, and hypophosphatemia. Currently, sorafenib is the first and only agent to demonstrate a beneficial overall survival (OS) and be approved by regulators globally in patients with advanced HCC [19].

## **3.2. Sunitinib**

Sunitinib (Sutent®) is an oral multi-RTK inhibitor targeting VEGFR-1, 2, and 3, PDGFRs, c-Kit, and other RTKs associated with angiogenesis [23]. Several phase II clinical trials have shown favorable results regarding the antitumor activity of this drug against advanced HCC. In one phase III trial, the median OS was 7.9 and 10.2 in the sunitinib and sorafenib groups, respectively [24]. This indicates that sunitinib had no benefit over sorafenib as a first-line therapy for advanced HCC.

## **3.3. Brivanib**

Brivanib, a dual tyrosine kinase inhibitor, shows potent and selective inhibition of VEGFR and FGFR [25]. Brivanib has exerted an anticancerous effect in xenograft human HCC models expressing FGF receptors [26]. Two phase III trials have been performed: (1) the BRISK-FL study, in which brivanib vs. sorafenib as first-line therapy was evaluated in patients with advanced HCC and (2) the BRISK-PS study, in which brivanib was administered to patients with advanced HCC who were resistant to sorafenib [27, 28]. However, both trials failed to meet the primary endpoint of statistically improving the OS rate.

## **3.4. Lenvatinib**

Lenvatinib (Lenvima®) is an oral multityrosine kinase inhibitor with potent antiangiogenic effects that has recently been approved for use in differentiated thyroid cancer [29]. The drug was established in patient-derived xenograft models that reliably recapitulated the genetic and phenotypic features of HCC [30]. Moreover, in models expressing high levels of FGF receptor 1, lenvatinib exhibited a greater efficacy than sorafenib. Lenvatinib has also shown highly promising data in phase I/II clinical trials involving patients with advanced HCC [31].

## **3.5. Cabozantinib**

extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) signaling pathway [20]. Such signaling results in a lower cyclin D1 expression as well as cell cycle arrest. Sorafenib also potently inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3, and c-Kit, which promote angiogenesis [19, 20]. The repression blocks a broad spectrum of different processes involved in proliferation, angiogenesis, or apoptosis, causing a reduction in the blood vessel regions of the tumor and the starving of cancerous cells. Furthermore, sorafenib enhances tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death through an SH2 domain, which causes a tyrosine phosphatase (SHP-1)-dependent reduction of signal transducers and activators of transcription type 3 (STAT3) phosphorylation and the related protein myeloid cell leukemia 1 (Mcl-1) (i.e., survivin and cyclin D1) in HCC cells [21]. Sorafenib is also able to repress Mcl-1 activity through an MAPK-independent mechanism, which increases the intrinsic apoptosis pathway in tumor cells. Moreover, recent studies have claimed that the eukaryotic translation initiation factor 4E (eIF4E) might be implicated in sorafenib-dependent Mcl-1 inhibition [22]. Clinically, sorafenib can extend the mean patient survival from 7.9 to 10.7 months [19]. Representative adverse events caused by the treatment of sorafenib consist of diarrhea, weight loss, hand-foot skin reaction, and hypophosphatemia. Currently, sorafenib is the first and only agent to demonstrate a beneficial overall survival (OS) and be approved by regulators globally in patients with advanced HCC

414 Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy

Sunitinib (Sutent®) is an oral multi-RTK inhibitor targeting VEGFR-1, 2, and 3, PDGFRs, c-Kit, and other RTKs associated with angiogenesis [23]. Several phase II clinical trials have shown favorable results regarding the antitumor activity of this drug against advanced HCC. In one phase III trial, the median OS was 7.9 and 10.2 in the sunitinib and sorafenib groups, respectively [24]. This indicates that sunitinib had no benefit over sorafenib as a first-line therapy for

Brivanib, a dual tyrosine kinase inhibitor, shows potent and selective inhibition of VEGFR and FGFR [25]. Brivanib has exerted an anticancerous effect in xenograft human HCC models expressing FGF receptors [26]. Two phase III trials have been performed: (1) the BRISK-FL study, in which brivanib vs. sorafenib as first-line therapy was evaluated in patients with advanced HCC and (2) the BRISK-PS study, in which brivanib was administered to patients with advanced HCC who were resistant to sorafenib [27, 28]. However, both trials failed to

Lenvatinib (Lenvima®) is an oral multityrosine kinase inhibitor with potent antiangiogenic effects that has recently been approved for use in differentiated thyroid cancer [29]. The drug was established in patient-derived xenograft models that reliably recapitulated the genetic and phenotypic features of HCC [30]. Moreover, in models expressing high levels of FGF receptor

meet the primary endpoint of statistically improving the OS rate.

[19].

**3.2. Sunitinib**

advanced HCC.

**3.3. Brivanib**

**3.4. Lenvatinib**

Cabozantinib (Cometriq®) was approved in 2012 by the FDA and is a small-molecule RTK inhibitor with potent activity toward VEGFR-2, MET, and RET (rearranged during transfection), leading to the inhibition of tumor angiogenesis [32]. In a phase II study, the observed disease control rate following 12 weeks of treatment with cabozantinib was found to be 68 or 78% of the patients with or without prior sorafenib treatment exhibited tumor regression. A phase III randomized double-blind, controlled trial is ongoing to compare the efficacy of cabozantinib with a placebo as the second-line treatment modality for advanced HCC patients who have previously received sorafenib.

## **4. Alternative therapy**

Sorafenib is the standard therapeutic agent administered for the treatment of advanced stages of HCC and it is likely that other RTK inhibitors will also become commonly utilized drugs. However, chronic liver damage usually lowers the capacity of drug metabolism in patients, and the long-term administration of sorafenib may induce excessive adverse effects. Therefore, to reduce dosage of sorafenib, an alternative approach may be required to identify a clinically available compound targeting tumor angiogenesis. Among the various factors to affect angiogenic activities, many researchers have focused their attention on the mechanisms of angiotensin-II (AT-II) and insulin resistance (IR). These factors have been shown to affect angiogenesis in the liver via close interactions [33]. Moreover, since these factors could also be involved in the HCC, the regulation of these factors might contribute to suppressing the progression of the chronic liver disease.

#### **4.1. RAAS blockers**

The renin-angiotensin-aldosterone system (RAAS) is a hormone system that is involved in the regulation of the plasma sodium concentration and arterial blood pressure to maintain body fluid homeostasis [34]. Recent reports have demonstrated that RAAS is locally expressed in a number of tissues, including the kidneys, adrenal glands, heart, vasculature and nervous system, and liver. Actually, RAAS is frequently activated in patients with chronic liver diseases, such as liver cirrhosis [35, 36]. AT-II is an octapeptide derived from its precursor, AT-I, after AT-I converting enzyme (ACE) acts AT-I, proteolytically cleaving the C-terminal dipeptide. During the progression of chronic liver diseases, AT-II is considered to be a potential mediator of portal hypertension. It has been reported that AT-II plasma levels are clinically increased in patients with cirrhosis, and an animal study has shown the elevation of the portal pressure by AT-II administration [37, 38].

AT-II plays a crucial role in the development of several cancers, including HCC. Lever et al. has previously shown the outcome of a retrospective cohort study consisting of 5207 patients with treatment of either an ACE inhibitor (ACE-I) or other antihypertensive agents such as calcium channel blockers, diuretics, and β-blockers with a 10-year follow-up (Glasgow study). Interestingly, in their study, the incidence of cancer and fetal cancer was decreased in the patients with ACE-I treatment as compared with those with other drugs [39]. A recent cohort study has also demonstrated a lower incidence of cancer in patients using ACE-I or an AT-II receptor blocker (ARB) than nonusers [40]. Furthermore, it has been reported that the addition of ACE-I or ARB provided the prolonged survival for the patients with advanced non–small cell lung cancer undergoing platinum-based chemotherapy [41]. Additionally, inhibition of RAAS possibly exerted the beneficial effects on the prognosis of patients with advanced hormone-refractory prostate cancer and pancreatic cancer receiving gemcitabine [42, 43]. In regard to liver cancer, ACE-I showed the suppressive effect on the tumor growth in a murine HCC experimental model [44].

The RAAS, especially AT-II, is potently involved in the regulation of both rarefaction and expansion of the vascular network. Circulating AT-II leads to drive a variety of signaling cascades leading to VEGF, FGF, IGF, and TGF-β expression through mainly binding to the AT1R on ECs [45–47]. AT-II/AT1-R axis plays a key role in the regulation of angiogenic activity in various pathological events, including tumor neovascularization. Actually, inhibition of AT-II by ACE-I and ARB reportedly attenuates **intratumoral neovascularization with downregulation of** VEGF expression in several cancers [48–50]. These findings indicate that ACE-I and ARB can be candidates for novel antiangiogenic agents against HCC. However, previous report has suggested that monotherapy with only antiangiogenic agent does not exert the sufficient effect on the prognosis in patients with advanced cancer [51]. Therefore, the combination treatment of antiangiogenic agents has been approached to show a synergistic inhibitory effect on cancer progression [51, 52]. For example, the combination of ACE-I and interferon (IFN) suppressed HCC growth more potently than monotherapy with ACE-I [53]. Our report demonstrated that the antitumoral effect of 5-fluorouracil (5-FU) is also enhanced by combination with ACE-I [54].

As well as tumor growth and metastasis, the early stages of carcinogenesis are also regulated by RAAS-mediated angiogenesis [5, 55]. Our animal study has shown that ACE-I significantly suppressed hepatocarcinogenesis at a clinically comparable low dose together with an attenuated neovascularization [56]. Additionally, a combination of ACE-I with supplementation of vitamin K (VK), which is often administered to the patients with osteoporosis, showed a more potent inhibitory effect on rat hepatocarcinogenesis than ACE-I monotherapy [57]. This combination regimen consisting of ACE-I and VK also exhibited the beneficial effect on ameliorating hepatocarcinogenesis in our clinical study [58]. A 48-month follow-up study revealed that a combined ACE-I with VK significantly suppressed the cumulative recurrence of HCC with reduced serum VEGF levels. The serum level of lectin-reactive α-fetoprotein (AFP-L3), known as one of the HCC tumor markers, was also decreased in parallel with VEGF. Accordingly, this combination regimen may represent a new strategy for chemoprevention against HCC.

Aldosterone (Ald), a downstream component of AT-II in RAAS, also affects in the regulation of angiogenesis. **Endocrinologically**, Ald is a mineralocorticoid hormone regulating the plasma sodium (Na+ ), the extracellular potassium (K+ ) and arterial blood pressure, blood pressure, and electrolyte balance via mineralocorticoid receptors (MR) [59]. Recent data have suggested that Ald plays a key role in endothelial dysfunction, as well as a suggested involvement in the pathogenesis of hypertension [60]. Moreover, the possible involvement of Ald and the MR systems in pathological ocular neovascularization has been reported [61]. Ald was shown to stimulate the proliferation and tubulogenesis of EC, and exacerbated angiogenesis in oxygen-induced retinopathy. In addition, these events could be attenuated by spironolactone. Eplerenone, a selective Ald blocker (SAB), is clinically used as a novel option for the treatment of hypertension. SAB is a selective MR antagonist with higher affinity than spironolactone, contributing to lower side effect by binding the progesterone and androgen receptors. The animal study revealed that murine hepatocarcinogenesis was markedly suppressed by the treatment of SAB with attenuation of VEGF-mediated angiogenesis [62]. These results indicate that SAB is also a viable option for treatment of HCC.

#### **4.2. Regulation of insulin resistance**

with treatment of either an ACE inhibitor (ACE-I) or other antihypertensive agents such as calcium channel blockers, diuretics, and β-blockers with a 10-year follow-up (Glasgow study). Interestingly, in their study, the incidence of cancer and fetal cancer was decreased in the patients with ACE-I treatment as compared with those with other drugs [39]. A recent cohort study has also demonstrated a lower incidence of cancer in patients using ACE-I or an AT-II receptor blocker (ARB) than nonusers [40]. Furthermore, it has been reported that the addition of ACE-I or ARB provided the prolonged survival for the patients with advanced non–small cell lung cancer undergoing platinum-based chemotherapy [41]. Additionally, inhibition of RAAS possibly exerted the beneficial effects on the prognosis of patients with advanced hormone-refractory prostate cancer and pancreatic cancer receiving gemcitabine [42, 43]. In regard to liver cancer, ACE-I showed the suppressive effect on the tumor growth in a murine

416 Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy

The RAAS, especially AT-II, is potently involved in the regulation of both rarefaction and expansion of the vascular network. Circulating AT-II leads to drive a variety of signaling cascades leading to VEGF, FGF, IGF, and TGF-β expression through mainly binding to the AT1R on ECs [45–47]. AT-II/AT1-R axis plays a key role in the regulation of angiogenic activity in various pathological events, including tumor neovascularization. Actually, inhibition of AT-II by ACE-I and ARB reportedly attenuates **intratumoral neovascularization with downregulation of** VEGF expression in several cancers [48–50]. These findings indicate that ACE-I and ARB can be candidates for novel antiangiogenic agents against HCC. However, previous report has suggested that monotherapy with only antiangiogenic agent does not exert the sufficient effect on the prognosis in patients with advanced cancer [51]. Therefore, the combination treatment of antiangiogenic agents has been approached to show a synergistic inhibitory effect on cancer progression [51, 52]. For example, the combination of ACE-I and interferon (IFN) suppressed HCC growth more potently than monotherapy with ACE-I [53]. Our report demonstrated that the antitumoral effect of 5-fluorouracil (5-FU) is also enhanced by combi-

As well as tumor growth and metastasis, the early stages of carcinogenesis are also regulated by RAAS-mediated angiogenesis [5, 55]. Our animal study has shown that ACE-I significantly suppressed hepatocarcinogenesis at a clinically comparable low dose together with an attenuated neovascularization [56]. Additionally, a combination of ACE-I with supplementation of vitamin K (VK), which is often administered to the patients with osteoporosis, showed a more potent inhibitory effect on rat hepatocarcinogenesis than ACE-I monotherapy [57]. This combination regimen consisting of ACE-I and VK also exhibited the beneficial effect on ameliorating hepatocarcinogenesis in our clinical study [58]. A 48-month follow-up study revealed that a combined ACE-I with VK significantly suppressed the cumulative recurrence of HCC with reduced serum VEGF levels. The serum level of lectin-reactive α-fetoprotein (AFP-L3), known as one of the HCC tumor markers, was also decreased in parallel with VEGF. Accordingly, this combination regimen may represent a new strategy for chemoprevention

Aldosterone (Ald), a downstream component of AT-II in RAAS, also affects in the regulation of angiogenesis. **Endocrinologically**, Ald is a mineralocorticoid hormone regulating the

HCC experimental model [44].

nation with ACE-I [54].

against HCC.

Recent studies have revealed a close relationship between IR and the progression of liver disease, including HCC [63, 64]. In general, chronic liver diseases impair the metabolic homeostasis of glucose as a result of IR, glucose intolerance, and DM [65]. Several clinical studies have also identified the hyperinsulinemia in patients with chronic hepatitis C (CHC) [66–68]. Experimental evidence with the HCV-transgenic mouse model confirms the contribution of HCV in the development of IR and DM [69]. In this model, the overproduced TNFα appears to play a pivotal role in the induction of IR and DM. TNF-α is a proinflammatory cytokine, dramatically elevated during inflammation-induced disease pathology. HCV itself induces the phosphorylation of the serine residues associated with the insulin receptor substrate (IRS)-1 and -2 and stimulates the overproduction of suppressor of cytokine-3 (SOC-3), inhibiting the phosphorylation of Akt/PI3K, leading to the blockade of transactivation of GLUT-4, which contributes to inhibit intracellular glucose uptake. Additionally, nonalcoholic fatty liver disease (NAFLD) is a common liver disorder associated with IR and DM [70]. Various factors participate in the progression of NAFLD, such as oxidative stress, endotoxemia, obesity, genetic factors, and IR. Several reports have suggested the association of IR and mitochondrial abnormalities [71].

Recently, a reciprocal relationship between diabetes and HCC has been noticed. A two to threefold increase in the risk of HCC has been observed in the patients with DM, regardless of the etiology of chronic liver diseases [72–74]. A large longitudinal study in the United States demonstrated the twofold higher incidence of HCC in the diabetic patients [74]. Moreover, a recent study has elucidated that the IR status directly facilitated hepatocarcinogenesis [64]. Hyperinsulinemia can generally induce the synthesis and activation of IGF-1, which has a potential to progress a variety of cancer [75]. The altered expression pattern of IGF-1 signaling has been found in human HCC as well as hepatocarcinogenesis in rodent models [76]. Furthermore, IR status may progress hepatocarcinogenesis through the augmentation of hepatic neovascularization and VEGF expression in a rat carcinogenesis model [64].

The diabetic patients with compensated liver diseases initially are treated by a lifestyle change. However, restrictive diets may be liable to aggravate malnutrition in some patients. Thus, the oral antidiabetic drugs are administered to treat the diabetic patients with advanced liver diseases such as cirrhosis [77, 78]. To avoid hyperinsulinemia affecting adversely HCC growth, the drugs exerting insulin-sensitizing effects are preferable such as metformin, pioglitazone, dipeptidyl peptidase 4 inhibitor, or sodium glucose cotransporter inhibitor. Another report has demonstrated that the use of statins, a class of lipid-lowering medications by inhibiting HMG-CoA reductase that plays a central role in the production of cholesterol, significantly lowered the risk of HCC in the patients with DM [79].

The branched-chain amino acid (BCAA), an amino acid having aliphatic side chains with a branch (a central carbon atom bound to three or more carbon atoms), comprises three essential amino acids: leucine, isoleucine, and valine. Several clinical studies have suggested the beneficial effect of the long-term supplementation with BCAA granules on hypoalbuminemia and event-free survival in the patients with cirrhosis [80, 81]. BCAAs have also been shown to induce glucose uptake and improve glucose metabolism in a rat cirrhotic model. Intriguingly, the animal study using obese diabetic rat showed a chemopreventive effect of BCAAs against HCC with the downregulation of VEGF and antiangiogenic activity [82, 83]. Multicenter study in Japan also revealed that BCAAs decreased the incidence of HCC in patients with HCVrelated cirrhosis as well as the type 2 DM and obesity [84]. However, a monotherapy with BCAA did not inhibit the recurrence of HCC after curative treatment. Therefore, to utilize BCAAs with sufficient effect against HCC, it is strongly recommended to combine them with other drugs. From previous research, AT-II also plays a key role in the development of IR. Actually, mice genetically lacking ACE exhibited the improvement of glucose tolerance through the reduced fat mass [85]. Moreover, additional administration of ACE-I or ARB to BCAAs is also shown to improve the IR status [33, 86]. Our randomized control trial study demonstrated that the combined BCAAs with ACE-I suppresses the cumulative recurrence of HCC in the patients with IR [87].

Taken together, these findings indicate that the combination of BCAAs supplementation and RAAS blockade may represent a potentially novel therapeutic strategy against HCC in the patients with IR.

## **5. Conclusions and future perspectives**

Angiogenesis plays a crucial role in hepatocarcinogenesis and HCC progression, indicating the requirement of an antiangiogenic therapy as a tool for suppressing HCC. Sorafenib has become a breakthrough drug in the field of HCC, with an improvement in the median survival of almost 3 months. This represents a reduction of greater than 30% for the probability of death during the follow-up period.

However, when using RTK inhibitors, including sorafenib for patients with chronic liver diseases, many patients exhibit adverse effects, and several symptoms are very severe. Since the adverse effects induced by RTK inhibitors emerge in a dose-dependent manner, it is desirable for patients with chronic liver diseases to avoid these drugs as much as possible. Therefore, to lower the dose of such treatments, a clinically available compound to use in combination with RTK inhibitors may be required.

ACE-I, ARB, and SAB are extensively employed as antihypertensive agents in clinical practice without serious adverse effects. Thus, these RAAS blocking agents may provide a novel strategy targeting HCC. However, several reports also suggest that there is a close relationship between AT-II polymorphisms and the progression of chronic liver diseases and cancers. In certain types of cancers, the elevated ACE genetic polymorphisms are significantly involved in their poor prognosis [88, 89]. Additionally, AT-II type I receptor polymorphism reportedly contributes to the occurrence of nonalcoholic steatohepatitis (NASH) [90]. These evidences suggest that the efficacy of RAAS inhibition may vary in each case. Since combination treatment of ACE-I and VK exerted substantially more potent inhibitory effects, a combination treatment involving these agents may be preferable for future clinical applications. Furthermore, under IR conditions, the combination treatment of BCAA and ACE-I would be a promising approach against HCC via the suppression of VEGF-mediated angiogenesis. Since these agents are widely used in clinical practice, the combination of these agents with RTK inhibitors such as sorafenib represents a potential alternative approach against HCC.

## **Author details**

The diabetic patients with compensated liver diseases initially are treated by a lifestyle change. However, restrictive diets may be liable to aggravate malnutrition in some patients. Thus, the oral antidiabetic drugs are administered to treat the diabetic patients with advanced liver diseases such as cirrhosis [77, 78]. To avoid hyperinsulinemia affecting adversely HCC growth, the drugs exerting insulin-sensitizing effects are preferable such as metformin, pioglitazone, dipeptidyl peptidase 4 inhibitor, or sodium glucose cotransporter inhibitor. Another report has demonstrated that the use of statins, a class of lipid-lowering medications by inhibiting HMG-CoA reductase that plays a central role in the production of cholesterol, significantly

The branched-chain amino acid (BCAA), an amino acid having aliphatic side chains with a branch (a central carbon atom bound to three or more carbon atoms), comprises three essential amino acids: leucine, isoleucine, and valine. Several clinical studies have suggested the beneficial effect of the long-term supplementation with BCAA granules on hypoalbuminemia and event-free survival in the patients with cirrhosis [80, 81]. BCAAs have also been shown to induce glucose uptake and improve glucose metabolism in a rat cirrhotic model. Intriguingly, the animal study using obese diabetic rat showed a chemopreventive effect of BCAAs against HCC with the downregulation of VEGF and antiangiogenic activity [82, 83]. Multicenter study in Japan also revealed that BCAAs decreased the incidence of HCC in patients with HCVrelated cirrhosis as well as the type 2 DM and obesity [84]. However, a monotherapy with BCAA did not inhibit the recurrence of HCC after curative treatment. Therefore, to utilize BCAAs with sufficient effect against HCC, it is strongly recommended to combine them with other drugs. From previous research, AT-II also plays a key role in the development of IR. Actually, mice genetically lacking ACE exhibited the improvement of glucose tolerance through the reduced fat mass [85]. Moreover, additional administration of ACE-I or ARB to BCAAs is also shown to improve the IR status [33, 86]. Our randomized control trial study demonstrated that the combined BCAAs with ACE-I suppresses the cumulative recurrence of

Taken together, these findings indicate that the combination of BCAAs supplementation and RAAS blockade may represent a potentially novel therapeutic strategy against HCC in the

Angiogenesis plays a crucial role in hepatocarcinogenesis and HCC progression, indicating the requirement of an antiangiogenic therapy as a tool for suppressing HCC. Sorafenib has become a breakthrough drug in the field of HCC, with an improvement in the median survival of almost 3 months. This represents a reduction of greater than 30% for the probability of death

However, when using RTK inhibitors, including sorafenib for patients with chronic liver diseases, many patients exhibit adverse effects, and several symptoms are very severe. Since the adverse effects induced by RTK inhibitors emerge in a dose-dependent manner, it is

lowered the risk of HCC in the patients with DM [79].

418 Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy

HCC in the patients with IR [87].

during the follow-up period.

**5. Conclusions and future perspectives**

patients with IR.

Kosuke Kaji\* and Hitoshi Yoshiji

\*Address all correspondence to: kajik@naramed-u.ac.jp

Third Department of Internal Medicine, Nara Medical University, Shijo-cho, Kashihara, Nara, Japan

## **References**


[20] Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews Drug Discovery. 2006;5(10):835–44.

[5] Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nature Reviews

[6] Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 1999;284(5415):808–12.

[7] Brandvold KA, Neiman P, Ruddell A. Angiogenesis is an early event in the generation

[8] Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroen-

[9] Kerbel RS. Tumor angiogenesis. The New England Journal of Medicine. 2008;358(19):

[10] Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69(Suppl

[11] Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in

[12] Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene. 2000;19(49):5598–605.

[13] Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma.

[14] Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology.

[15] Yamaguchi R, Yano H, Nakashima Y, Ogasawara S, Higaki K, Akiba J, et al. Expression and localization of vascular endothelial growth factor receptors in human hepatocel-

[16] Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, et al. Halting the interaction between vascular endothelial growth factor and its receptors attenuates

[17] Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects.

[18] Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–

[19] Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine. 2008;359(4):378–90.

lular carcinoma and non-HCC tissues. Oncology Reports. 2000;7(4):725–9.

liver carcinogenesis in mice. Hepatology. 2004;39(6):1517–24.

CA: Cancer Journal for Clinicians. 2010;60(4):222–43.

of myc-induced lymphomas. Oncogene. 2000;19(23):2780–5.

420 Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy

angiogenesis. Cell Structure and Function. 2001;26(1):25–35.

Cancer. 2003;3(6):401–10.

2039–49.

3):4–10.

1998;28(1):68–77.

55.

terology. 2004;127(5 Suppl 1):S218–24.

Journal of Hepatology. 1997;27(5):854–61.


[43] Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, et al. Inhibition of reninangiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. British Journal of Cancer. 2010;103(11):1644–8.

[31] Oikonomopoulos G, Aravind P, Sarker D. Lenvatinib: a potential breakthrough in

[32] Xiang Q, Chen W, Ren M, Wang J, Zhang H, Deng DY, et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clinical Cancer Research: An Official Journal of the American

[33] de Kloet AD, Krause EG, Woods SC. The renin angiotensin system and the metabolic

[34] Ardaillou R. Angiotensin II receptors. Journal of the American Society of Nephrology:

[35] Helmy A, Jalan R, Newby DE, Hayes PC, Webb DJ. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis.

[36] Munshi MK, Uddin MN, Glaser SS. The role of the renin-angiotensin system in liver

[37] Beyazit Y, Ibis M, Purnak T, Turhan T, Kekilli M, Kurt M, et al. Elevated levels of circulating angiotensin converting enzyme in patients with hepatoportal sclerosis.

[38] Lugo-Baruqui A, Munoz-Valle JF, Arevalo-Gallegos S, Armendariz-Borunda J. Role of angiotensin II in liver fibrosis-induced portal hypertension and therapeutic implications. Hepatology Research: the Official Journal of the Japan Society of Hepatology.

[39] Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet.

[40] Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA, Trial V. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. Journal of the National Cancer Institute. 2008;100(17):

[41] Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinumbased chemotherapy. Journal of Cancer Research and Clinical Oncology. 2009;135(10):

[42] Uemura H, Hasumi H, Kawahara T, Sugiura S, Miyoshi Y, Nakaigawa N, et al. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate

cancer. International Journal of Clinical Oncology. 2005;10(6):405–10.

fibrosis. Experimental Biology and Medicine. 2011;236(5):557–66.

Digestive Diseases and Sciences. 2011;56(7):2160–5.

advanced hepatocellular carcinoma? Future Oncology. 2016;12(4):465–76.

Association for Cancer Research. 2014;20(11):2959–70.

422 Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy

syndrome. Physiology & Behavior. 2010;100(5):525–34.

JASN. 1999;10(Suppl 11):S30–9.

2010;40(1):95–104.

1223–32.

1429–35.

1998;352(9123):179–84.

Gastroenterology. 2000;118(3):565–72.


[67] Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology. 2003;125(6):1695–704.

[55] Staton CA, Chetwood AS, Cameron IC, Cross SS, Brown NJ, Reed MW. The angiogenic switch occurs at the adenoma stage of the adenoma carcinoma sequence in colorectal

[56] Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Tsujinoue H, et al. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells.

[57] Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, et al. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression.

[58] Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, et al. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. Journal of Hepatology. 2009;51(2):315–21. [59] Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action.

[60] Funder JW. Minireview: Aldosterone and mineralocorticoid receptors: past, present,

[61] Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal

[62] Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, Shirai Y, et al. Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice. Hepatology Research: The Official Journal of the Japan Society of Hepatology.

[63] Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcino-

[64] Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, Yoshii J, et al. Impact of insulin resistance on the progression of chronic liver diseases. International Journal of Molec-

[65] Nielsen MF, Caumo A, Aagaard NK, Chandramouli V, Schumann WC, Landau BR, et al. Contribution of defects in glucose uptake to carbohydrate intolerance in liver cirrhosis: assessment during physiological glucose and insulin concentrations. American journal of physiology Gastrointestinal and Liver Physiology. 2005;288(6):G1135–

[66] Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling The American Journal of Pathology. 2004;165(5):1499–508.

cancer. Gut. 2007;56(10):1426–32.

International Journal of Oncology. 2002;20(6):1227–31.

424 Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy

Journal of Hepatology. 2005;42(5):687–93.

Heart Failure Reviews. 2005;10(1):7–13.

2010;40(5):540–9.

43.

ular Medicine. 2008;22(6):801–8.

and future. Endocrinology. 2010;151(11):5098–102.

ma in Journal of Hepatology. 2008;48 Suppl 1:S20–37.

vascular pathology. Circulation Research. 2009;104(1):124–33.


[89] Medeiros R, Vasconcelos A, Costa S, Pinto D, Lobo F, Morais A, et al. Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. The Journal of Pathology. 2004;202(3):330–5.

[79] El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes.

[80] Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-

[81] Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology: The Official Clinical Practice

[82] Yoshiji H, Noguchi R, Kaji K, Ikenaka Y, Shirai Y, Namisaki T, et al. Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor

[83] Yoshiji H, Noguchi R, Kitade M, Kaji K, Ikenaka Y, Namisaki T, et al. Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic

[84] Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatology Research: The Official

[85] Jayasooriya AP, Mathai ML, Walker LL, Begg DP, Denton DA, Cameron-Smith D, et al. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proceedings of the National

[86] Manrique C, Lastra G, Gardner M, Sowers JR. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. The Medical Clinics of

[87] Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Yamazaki M, et al. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial.

[88] Fabris C, Smirne C, Fangazio S, Toniutto P, Burlone M, Minisini R, et al. Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C. Hepatology Research: The Official Journal of the Japan

Academy of Sciences of the United States of America. 2008;105(18):6531–6.

Journal of the American Gastroenterological Association. 2005;3(7):705–13.

in obese diabetic rats. Journal of Gastroenterology. 2010;45(4):443–50.

rats. Journal of Gastroenterology. 2009;44(5):483–91.

North America. 2009;93(3):569–82.

Oncology Reports. 2011;26(6):1547–53.

Society of Hepatology. 2009;39(8):795–804.

Journal of the Japan Society of Hepatology. 2006;35(3):204–14.

blind, randomized trial. Gastroenterology. 2003;124(7):1792–801.

426 Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy

Gastroenterology. 2009;136(5):1601–8.

[90] Yoneda M, Hotta K, Nozaki Y, Endo H, Uchiyama T, Mawatari H, et al. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver International: Official Journal of the International Association for the Study of the Liver. 2009;29(7):1078–85.

**Provisional chapter**
